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he evolution of automation in hematology has enabled
reater reliability and accuracy in the results of the complete
lood count (CBC) and the implementation of new technolo-
ies has streamlined the laboratory routine, optimizing the
ime to release tests. Moreover, new laboratory parameters
ave been recognized as auxiliaries to recognize some clinical
onditions.
From the ﬁrst platelet count performed in a chamber devel-
ped by Neubauer in 19241 to the present day, there have been
ncreasing improvements in the technology used to identify
nd quantify platelets. The new generation of hematology
nalyzers are more  accurate to identify cells, providing reli-
bility in the measurement of platelets particularly in cases of
evere thrombocytopenia. In addition, the use of ﬂuorescent
arkers speciﬁc for platelets allows the detection of possible
nterference, for example by decreasing the possibility of cases
f false thrombocytosis.2
Aspects related to the identiﬁcation of immature platelets,
ermed reticulated platelets (RP), date back to 1969. Nucleic
cid dyes allowed the detection of younger platelets using
n optical microscopy.3 Thiazole orange dye ﬂow cytometry
nd the strategy of the ‘gate’ were introduced later for iden-
ifying RP.4,5 More  recently some hematologic analyzers have
ade it possible to detect newly-released immature platelets.
he main clinical applicability of the immature platelet frac-
ion (IPF) is the evaluation of thrombopoietic activity in the
one marrow. An elevated number of immature circulat-
ng platelets is observed in thrombocytopenia of peripheral
rigin caused by excessive consumption of platelets, while
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is characterized by a reduced number of immature platelets
entering into the circulation.6–8
Another IPF application is the monitoring of the throm-
bocytopenic phase after chemotherapy and the transplant
of precursor cells.7,8 As younger platelets apparently have
greater thrombotic potential and are metabolically and enzy-
matically more  active than adult platelets, some studies
propose monitoring of the RP or IPF as indicators of risk for
acute coronary syndrome and other inﬂammatory and throm-
botic conditions.9
The same technological evolution in terms of accuracy, and
availability of new parameters was observed in the erythroid
series. The reticulocyte (RTC) count is clinically important both
for the pathophysiological classiﬁcation of anemia, and to
monitor marrow response after therapeutic interventions.10
However, for a long time the RTC count was underused in
the clinical and laboratory practice due to three main fac-
tors: technical limitations in the detection of the cell, the
imprecision of the manual microscopic method, and high
coefﬁcient of variations in counts. With the advent of automa-
tion, the detection and quantiﬁcation of these cells are much
more accurate and reliable, returning credibility and clini-
cal value to RTC enumeration. Similar to what occurred with
platelets, new parameters related to the degree of immatu-
rity of these precursors of red blood cells were introduced310–313.
ua do Paraíso 148, cj 31, CEP 04103-000, São Paulo, SP, Brazil.
by several hematologic analyzer manufacturers. Initially, it
was possible to subdivide the reticulocyte population in dif-
ferent degrees of maturity according to the content of RNA
inside the cell: more  immature reticulocytes have a higher
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ﬂuorescence intensity than mature cells. The immature retic-
ulocyte fraction (IRF) provides the same information obtained
by the reticulocyte count regarding the evaluation of bone mar-
row response to anemia or erythropoietic activity in general.10
The advantage is the precocity of the information provided by
IRF compared to the RTC count. In cases of regenerative ane-
mia  or response to replacement therapy, elevations in the IRF
value precede the increase in the absolute number of retic-
ulocytes by several days. For this reason, it is suggested that
the IRF should be used as an aid in the evaluation of bone
marrow response during mobilization of hematopoietic pre-
cursor cells,11 or as a predictor of recovery from neutropenia
in autologous transplantation.12
The measurement of the content of hemoglobin of reticu-
locytes (CHr or Ret-He) reﬂects the synthesis of hemoglobin in
marrow precursors, and allows the detection of early stages
of iron deﬁciency.13 This parameter has been identiﬁed as an
auxiliary in the differential diagnosis of anemias.14 The main
advantages of Ret-He are that it is released at the same time
as the CBC, and it is more  accurate than biochemical mark-
ers, such as ferritin and transferrin saturation in detecting
iron-deﬁcient erythropoiesis in patients with inﬂammation or
anemia of chronic disease.10
In the practice, the determination of Ret-He has been
more  widely used in patients with chronic kidney disease
undergoing a dialysis regime and recombinant human eryth-
ropoietin (rHuEPO).15,16 Under these conditions suitable iron
intake is imperative for adequate erythropoiesis. Biochemi-
cal dosages have shown limitations in the evaluation of iron
status in this group of patients, because they can suffer any
effect of inﬂammatory activity. Reticulocyte hemoglobin con-
tent measurement is incorporated into the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative (NKF-
K/DOQI) guidelines to monitor rHuEPO therapy.17
Limitations in the wider use of these new hematological
parameters are related to the lack of standardization and the
establishment of reference values for the normal population,
Therefore, since the technologies and the nomenclature of
new indexes vary according to the manufacturer, it is difﬁcult
to compare numeric results obtained from different analyzers.
In the study reported by Morkis et al.,18 132 samples of
apparently healthy individuals were evaluated in order to
establish the reference ranges for IRF, Ret-He and IPF. The
observed results are in agreement with published data giving
greater reliability in the investigation of the clinical appli-
cations of the parameters, and in the analysis of possible
alterations found on comparing results from patients with
values obtained in the normal population.
The establishment of reference values is a practice that
should be adopted whenever a new test is introduced in the
laboratory routine. In addition, a harmonization is needed for
new parameters and indices between different analyzers.
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